![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PROSER2 |
Gene summary for PROSER2 |
![]() |
Gene information | Species | Human | Gene symbol | PROSER2 | Gene ID | 254427 |
Gene name | proline and serine rich 2 | |
Gene Alias | C10orf47 | |
Cytomap | 10p14 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q86WR7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
254427 | PROSER2 | C04 | Human | Oral cavity | OSCC | 1.29e-03 | 3.15e-01 | 0.2633 |
254427 | PROSER2 | C21 | Human | Oral cavity | OSCC | 6.10e-04 | 1.93e-01 | 0.2678 |
254427 | PROSER2 | C30 | Human | Oral cavity | OSCC | 7.55e-18 | 7.97e-01 | 0.3055 |
254427 | PROSER2 | C43 | Human | Oral cavity | OSCC | 3.07e-03 | 1.35e-01 | 0.1704 |
254427 | PROSER2 | C46 | Human | Oral cavity | OSCC | 9.26e-08 | 2.36e-01 | 0.1673 |
254427 | PROSER2 | C57 | Human | Oral cavity | OSCC | 7.22e-15 | 4.40e-01 | 0.1679 |
254427 | PROSER2 | C06 | Human | Oral cavity | OSCC | 3.15e-05 | 8.52e-01 | 0.2699 |
254427 | PROSER2 | C08 | Human | Oral cavity | OSCC | 2.80e-04 | 1.21e-01 | 0.1919 |
254427 | PROSER2 | LN46 | Human | Oral cavity | OSCC | 1.93e-10 | 4.69e-01 | 0.1666 |
254427 | PROSER2 | SYSMH1 | Human | Oral cavity | OSCC | 4.68e-03 | 1.69e-01 | 0.1127 |
254427 | PROSER2 | SYSMH2 | Human | Oral cavity | OSCC | 3.53e-05 | 2.60e-01 | 0.2326 |
254427 | PROSER2 | SYSMH3 | Human | Oral cavity | OSCC | 1.77e-17 | 4.65e-01 | 0.2442 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PROSER2 | SNV | Missense_Mutation | novel | c.451N>A | p.Asp151Asn | p.D151N | Q86WR7 | protein_coding | tolerated(0.09) | possibly_damaging(0.876) | TCGA-RS-A6TP-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PROSER2 | SNV | Missense_Mutation | novel | c.625N>A | p.Glu209Lys | p.E209K | Q86WR7 | protein_coding | tolerated(0.07) | possibly_damaging(0.799) | TCGA-RS-A6TP-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PROSER2 | SNV | Missense_Mutation | rs758163603 | c.50N>T | p.Thr17Met | p.T17M | Q86WR7 | protein_coding | tolerated(1) | benign(0.005) | TCGA-BR-4368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PROSER2 | SNV | Missense_Mutation | rs771367449 | c.733N>T | p.Pro245Ser | p.P245S | Q86WR7 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-BR-6566-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PROSER2 | SNV | Missense_Mutation | novel | c.404N>T | p.Ala135Val | p.A135V | Q86WR7 | protein_coding | tolerated(0.67) | benign(0) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |